الفهرس 
Introduction and RationaleOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Uterine fibroids are the most common benign tumour of the female genital tract. Myomectomy has been the procedure of choice for symptomatic myomas in women desiring retention of the uterus.
Myomectomy is traditionally regarded as a surgical procedure that carries a major risk of intra-operative bleeding. This is due to increased vascularity of the fibroid uterus. The fibroid itself has poor vascularity, but the surrounding myometrium has a rich network of blood vessels.
It was recognized that extensive tissue injury can shift the haemostatic equilibrium towards fibrinolysis, contributing to coagulopathy and bleeding. Antifibrinolytic agents, mainly tranexamic acid, have been demonstrated to reduce blood loss and transfusion requirements in various elective surgeries.
Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of the lysine binding sites on plasminogen molecules.
Aim of the study was to evaluate the efficacy of tranexamic acid in decreasing blood loss during and after myomectomy.
The study was carried out in the Department of Obstetrics and Gynecology at Suez Canal University Teaching Hospital as a prospective randomized clinical trial during the period from October 2013 till October 2014 on 66 women undergoing myomectomy via laparotomy and who fulfilled the selection criteria. They were equally divided into two groups:
group I (study group): contained 33 women who received tranexamic acid 15-20 min before skin incision.
group II (control group): contained 33 women who did not receive tranexamic acid before myomectomy.